4月16日 -
** 哥伦比亚广播公司（CBS）新闻援引消息人士的话报道，美国总统特朗普计划签署行政命令，进一步研究伊博格碱，迷幻药开发商的股票随之上涨
** Compass Pathways CMPS.O、Enveric ENVB.O和Atai ATAI.O等开发迷幻药治疗神经精神疾病的公司股价分别上涨5.8%、6.4%和5.4%。
** 伊博格碱是从一种原产于非洲的灌木中提取的精神活性化合物，据报道可以减轻戒断症状以及与阿片类药物、酒精和尼古丁有关的渴求。
** 特朗普政府目前不打算将伊博格碱重新归类为医疗用途，因此伊博格碱仍是附表一物质--哥伦比亚广播公司（CBS）
** 计入当日表现，CMPS和ENVB分别下跌了9.4%和39%，而ATAI则上涨了4%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.